10-K: KalVista Pharmaceuticals Secures Landmark FDA Approval for Oral HAE Therapy EKTERLY, Bolstering Global Commercialization Efforts

KalVista Pharmaceuticals, Inc. announced the landmark U.S. FDA approval of EKTERLY (sebetralstat), the first and only oral, on-demand therapy for hereditary angioedema (HAE) in patients aged 12 and older, alongside strategic global commercialization partnerships and a significant royalty financing deal.

Summary

• The U.S. Food and Drug Administration (FDA) approved EKTERLY (sebetralstat) on July 3, 2025, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older, making it the first and only oral, on-demand therapy for HAE.
• The efficacy and safety of EKTERLY were established by the Phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine in May 2024, which met all primary and key secondary endpoints and demonstrated a favorable safety profile.
• HAE attacks treated with 600 mg of sebetralstat achieved symptom relief significantly faster than placebo (median time of 1.79 hours vs. 6.72 hours for placebo, p=0.0013), with treatment-related adverse event rates of 2.2% for sebetralstat compared to 4.8% for placebo.
• The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for sebetralstat in August 2024, and MAA submissions were also made to the United Kingdom, Switzerland, Australia, and Singapore in September 2024.
• Japan's Ministry of Health, Labour and Welfare (MHLW) granted sebetralstat orphan drug designation and received an NDA submission in January 2025, with an anticipated decision in early 2026.
• In November 2024, KalVista entered a Purchase and Sale Agreement with DRI Healthcare Acquisitions LP, receiving an upfront payment of $100.0 million in exchange for tiered royalties on worldwide net sales of sebetralstat (5.00% up to $500M, 1.10% on $500M-$750M, 0.25% above $750M).
• KalVista has an option to receive an additional one-time payment of $22.0 million if sebetralstat was approved prior to October 1, 2025, which was elected on July 7, 2025, increasing the first-tier royalty rate to 6.00% and a potential sales-based milestone from $50.0 million to $57.0 million if annual global net sales exceed $550.0 million before January 1, 2031.
• In April 2025, KalVista licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd., receiving an $11.0 million upfront payment on June 20, 2025, with potential for up to $11.0 million upon a regulatory milestone (anticipated early 2026), up to $2.0 million in commercial milestones, and royalties in the mid-twenties percentage of Japan National Health Insurance (NHI) price.
• A Licensing Agreement was also entered with Pendopharm (Pharmascience, Inc.) on June 26, 2025, for exclusive rights to manage regulatory approval and commercialization of sebetralstat in Canada.
• Net cash used in operating activities increased to $152.9 million for the fiscal year ended April 30, 2025, compared to $89.2 million in the prior fiscal year.
• The company reported an accumulated deficit of $653.2 million as of April 30, 2025, with cash, cash equivalents, and marketable securities totaling $220.6 million.
• Research and development expenses decreased by $14.5 million to $71.7 million in FY2025, while general and administrative expenses increased by $62.0 million to $116.3 million, primarily due to the build-out of the commercial and sales organization.
• The net loss for FY2025 was $183.4 million, compared to $126.6 million for FY2024.
• The Board approved a change to the company's fiscal year end from April 30 to December 31, effective for the 2026 fiscal year.
• As of April 30, 2025, the company had 270 full-time employees, an increase from 150 employees as of April 30, 2024.

Sentiment

Score: 8

Explanation: The FDA approval of EKTERLY is a major positive catalyst, establishing the company as a commercial-stage entity with the first oral on-demand HAE therapy. This significantly de-risks the primary asset. Strategic partnerships and substantial financing further strengthen its position. However, the company still faces significant losses, increased operating expenses for commercialization, and intense competition, along with the inherent uncertainties of drug commercialization and market acceptance. The delay in PDUFA date was minor and resolved quickly.

Positives

• U.S. FDA approval of EKTERLY (sebetralstat) on July 3, 2025, as the first and only oral, on-demand therapy for HAE in patients aged 12 and older, addressing a significant unmet medical need.
• Successful Phase 3 KONFIDENT clinical trial results, meeting all primary and key secondary endpoints with a favorable safety profile, supporting the drug's efficacy and tolerability.
• Secured a significant upfront payment of $100.0 million from DRI Healthcare Acquisitions LP through a royalty financing agreement, providing substantial non-dilutive capital.
• Elected to receive an additional $22.0 million payment from DRI due to early FDA approval, further strengthening the financial position.
• Established a strategic commercialization partnership in Japan with Kaken Pharmaceutical, Co., Ltd., including an $11.0 million upfront payment and potential for additional milestones and royalties.
• Expanded global reach through MAA submissions in Europe, UK, Switzerland, Australia, and Singapore, and a licensing agreement for Canada.
• Received multiple regulatory designations for sebetralstat, including FDA Fast Track and Orphan Drug, Japan MHLW Orphan Drug, and UK MHRA Innovation Passport, which can expedite development and provide market exclusivity benefits.
• Completed enrollment in the KONFIDENT-KID pediatric clinical trial for an orally disintegrating tablet (ODT) formulation of sebetralstat, potentially expanding the treatable patient population.
• Maintained a strong cash and marketable securities balance of $220.6 million as of April 30, 2025, which is anticipated to fund operations for at least the next twelve months and longer-term obligations.

Negatives

• Continued to incur significant operating losses since inception, with an accumulated deficit of $653.2 million as of April 30, 2025.
• Net loss increased to $183.4 million in FY2025 from $126.6 million in FY2024, indicating growing expenses.
• Net cash used in operating activities increased to $152.9 million in FY2025 from $89.2 million in FY2024, reflecting higher cash burn.
• Expectation to incur losses over the next several years and may never achieve or maintain profitability, which is a common challenge for biopharmaceutical companies.
• Heavy dependence on the successful commercialization of EKTERLY and the development/approval of future product candidates, concentrating business risk.
• Lack of prior experience in successfully conducting commercial activities, posing execution risks for product launch and market penetration.
• Faces substantial competition in the HAE treatment market from major pharmaceutical and biotechnology companies with established products and pipelines.
• Uncertainty regarding third-party payor coverage and adequate reimbursement levels for EKTERLY, which could severely hinder commercial success and profitability.
• Clinical drug development is inherently lengthy, expensive, and uncertain, with potential for delays, increased costs, or abandonment of programs.
• Risk of serious adverse events or unacceptable side effects being identified during ongoing clinical trials or post-approval, which could impact product viability.
• Reliance on third parties for manufacturing increases supply chain risks, including potential for insufficient quantities, unacceptable cost/quality, or delays.
• Future capital raises may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Stock price is volatile and may decline if projected development goals or commercialization targets are not met.
• Impact of the Inflation Reduction Act (IRA) and other healthcare reforms could lead to further reductions in drug pricing and reimbursement.
• Potential limitations on the ability to utilize net operating losses (NOLs) due to past ownership changes, with an estimated $76.7 million of federal NOLs expected to go unutilized.

Risks

• The company has incurred significant losses since inception and expects to continue incurring losses for several years, potentially never achieving or maintaining profitability.
• Substantial additional funding may be required for clinical development and commercial launch, and inability to raise capital could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• The company is heavily dependent on the successful commercialization of EKTERLY (sebetralstat) and the development, regulatory approval, and commercialization of its current and future product candidates.
• The company has not yet demonstrated an ability to successfully conduct commercial activities.
• Failure to achieve the necessary degree of market acceptance by physicians, patients, third-party payors, and others in the medical community could hinder commercial success.
• Sales, marketing, and distribution of EKTERLY or any future approved products may be unsuccessful or less successful than anticipated.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing competing products before or more successfully.
• Inability to achieve and maintain third-party payor coverage and adequate levels of reimbursement for EKTERLY or other approved product candidates could severely hinder commercial success.
• Clinical drug development is a lengthy and expensive process with an uncertain outcome, potentially leading to additional costs or delays.
• Failure to achieve projected development goals in announced timeframes could delay commercialization and lead to a decline in stock price.
• Identification of serious adverse events or unacceptable side effects during development may lead to abandonment or limitation of product development.
• Delays in obtaining required regulatory approvals would prevent commercialization and materially impair revenue generation.
• Operations and relationships with healthcare providers are subject to anti-bribery, anti-kickback, fraud, and abuse, and other healthcare laws and regulations, potentially leading to enforcement actions.
• Orphan drug designation by regulatory authorities does not guarantee marketing exclusivity.
• Failure to obtain regulatory approval in international jurisdictions would prevent EKTERLY and other product candidates from being marketed abroad.
• Approved products are subject to extensive post-marketing regulatory requirements and could be subject to restrictions or withdrawal from the market.
• Reliance on third parties for manufacturing EKTERLY and other product candidates increases the risk of insufficient quantities, unacceptable cost/quality, or delays.
• Failure of collaborations with third parties for development and commercialization could prevent capitalization on market potential.
• Inability to obtain and maintain intellectual property protection or insufficient scope of protection could allow competitors to commercialize similar products.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel.
• The company's stock price is volatile, and stockholders may not be able to resell shares at or above the price paid.
• Shareholder activism could cause material disruption to the business.
• Provisions in charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
• Unstable or unfavorable global market and economic conditions may have adverse consequences on the business, financial condition, and stock price.
• Changes in tax laws or tax rulings could materially affect the financial position, results of operations, and cash flows.
• If securities or industry analysts do not publish research or reports about the business, or if they issue an adverse opinion, stock price and trading volume could decline.
• The company does not currently intend to pay dividends on its common stock, so return on investment depends on stock price appreciation.
• Actual or perceived failure to comply with privacy and data security laws, regulations, and standards may materially adversely affect the business.
• Business and operations would suffer in the event of system failures, cyberattacks, or a deficiency in cybersecurity.
• The ability to use net operating losses (NOLs) to offset future taxable income may be subject to certain limitations, with approximately $76.7 million of federal NOLs expected to go unutilized.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future as it commercializes EKTERLY and advances its pipeline. Expenses are anticipated to increase substantially due to the build-out of commercial infrastructure for EKTERLY's launch. Management believes current cash and anticipated EKTERLY sales will be sufficient to fund operations for at least the next 12 months and longer-term obligations, but acknowledges the potential need for additional external funding. The strategic focus is on positioning EKTERLY as a foundational HAE therapy globally through direct efforts and partnerships, while also developing a sustainable pipeline, particularly oral Factor XIIa inhibitors, and evaluating strategic in-licensing or acquisition opportunities.

Management Comments

• "We believe EKTERLY (sebetralstat) has the potential to fundamentally shift the manner in which HAE is managed, based upon extensive and continuing research conducted with patients, physicians and payers."
• "We believe EKTERLY (sebetralstat) with its effectiveness as a tablet compared to injectable treatment options, its ability to treat all attacks and to enable early treatment, provides a new and unique opportunity for patients and healthcare providers to revise their approach to HAE disease management."
• "Through our present and future patient and healthcare provider outreach, we anticipate that awareness of EKTERLYs (sebetralstat) utility will create sustained and long-lasting demand."
• "We believe that a safe and effective oral on-demand agent has the potential to transform treatment for this disease."
• "We believe our preclinical oral Factor XIIa inhibitor program has the potential to be the first orally delivered Factor XIIa inhibitor for indications across a wide variety of therapeutic areas that are supported by scientific evidence."
• "We believe that this team, leveraging their experience, strong execution capabilities, and financial discipline, will enable the Company to continue to innovate and grow."
• "We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees."
• "We believe that our current and future facilities will be adequate for the foreseeable future."
• "Our working capital, primarily cash and marketable securities, is anticipated to be sufficient to fund our operations for at least the next twelve months from the date these consolidated financial statements are issued."
• "The Company anticipates cash flows from the sale of EKTERLY."

Industry Context

Hereditary Angioedema (HAE) is a rare, life-threatening genetic condition affecting approximately 1 in 35,000 to 1 in 50,000 people, characterized by unpredictable and potentially fatal swelling attacks. Existing on-demand treatments are primarily injectable, imposing a significant burden on patients and often leading to delayed administration despite the known benefits of early treatment. KalVista's EKTERLY, as the first oral on-demand therapy, addresses a major unmet need for convenience and accessibility, positioning it to potentially transform HAE management. The HAE market is competitive, with several approved injectable prophylactic and on-demand therapies, and a pipeline of other companies developing HAE treatments, including oral and gene-editing approaches. The broader biopharmaceutical industry faces increasing scrutiny over drug pricing and reimbursement, particularly from U.S. healthcare reforms like the Inflation Reduction Act, which could impact market access and profitability.

Comparison to Industry Standards

• EKTERLY (sebetralstat) is positioned as the first and only oral, on-demand therapy for HAE, offering a significant convenience advantage over currently approved injectable on-demand treatments such as Takeda's FIRAZYR and KALBITOR, CSL Behring's BERINERT, and Pharming Group's RUCONEST.
• The Phase 3 KONFIDENT trial demonstrated a median time to beginning of symptom relief of 1.79 hours for EKTERLY (600mg) compared to 6.72 hours for placebo, highlighting its rapid action compared to no treatment, and potentially enabling earlier intervention than injectable options which often face administration delays.
• In the prophylactic HAE market, competitors include Takeda's TAKHZYRO, CSL Behring's HAEGARDA and ANDEMBRY, and BioCryst Pharmaceuticals' ORLADEYO (an oral prophylactic). EKTERLY's on-demand indication complements, rather than directly competes with, prophylactic therapies, addressing breakthrough attacks.
• Other companies in clinical development for HAE treatments, such as Pharvaris GmbH (oral B2R inhibitor deucrictibant IR/XR in Phase 3) and Ionis Pharmaceuticals, Inc. (donidalorsen, an antisense inhibitor of prekallikrein synthesis, with an August 21, 2025 PDUFA date), represent future competition, but KalVista has achieved the first oral on-demand approval.
• The company's focus on an oral plasma kallikrein inhibitor aligns with a clinically validated target for HAE, as many approved therapies inhibit plasma kallikrein.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased share value due to FDA approval and global commercialization efforts, but also risk of dilution from future capital raises and stock price volatility. No dividends are planned, so return depends on appreciation. Subject to risks from shareholder activism.
• **Patients (HAE)**: Significant positive impact by providing the first oral, on-demand treatment option (EKTERLY), offering greater convenience and potentially enabling earlier intervention for acute HAE attacks.
• **Physicians/Healthcare Providers**: Introduction of a novel oral therapy for HAE, which may require education and could lead to a shift in treatment paradigms from injectable options.
• **Employees**: Company growth indicated by increased headcount (from 150 to 270 employees), with a focus on attracting and retaining skilled personnel for commercialization. Employees are subject to the new insider trading policy.
• **Commercial Partners (Kaken Pharmaceutical, Pendopharm)**: Kaken gains exclusive commercialization rights in Japan, and Pendopharm in Canada, expanding their product portfolios and market presence.
• **Royalty Partner (DRI Healthcare Acquisitions LP)**: DRI Healthcare benefits from tiered royalty payments on global net sales of EKTERLY, providing a return on their upfront investment.
• **Regulatory Authorities**: Continued engagement with FDA, EMA, MHLW, MHRA, Swissmedic, TGA, and HSA for ongoing regulatory reviews and compliance, ensuring product safety and efficacy standards are met.

Next Steps

• Commercial launch of EKTERLY (sebetralstat) in the U.S. following FDA approval.
• Continued review of Marketing Authorization Application (MAA) for sebetralstat by the European Medicines Agency (EMA) for 27 EU Member States and EEA countries.
• Review of MAA submissions in the United Kingdom, Switzerland, Australia, and Singapore via the Access Consortium framework.
• Review of New Drug Application (NDA) for sebetralstat by Japan's Ministry of Health, Labour and Welfare (MHLW), with an anticipated decision in early 2026.
• Preparation of internal sales and marketing teams for Germany and the UK in anticipation of marketing application decisions in the second half of 2025.
• Anticipated receipt of an additional regulatory milestone payment of up to $11.0 million from Kaken Pharmaceutical in early 2026.
• Strategic review of the preclinical oral Factor XIIa inhibitor program to evaluate further progress and indications, including potential partnerships.
• Filing a transition report on Form 10-K for the eight-month period of May 1, 2025, through December 31, 2025, due to the change in fiscal year.
• Filing a Quarterly Report on Form 10-Q for the quarter ending July 31, 2025, and subsequent quarterly reports based on the new fiscal year beginning with the quarter ending September 30, 2025.
• Potential sale of up to $100,000,000 of common stock under the at-the-market (ATM) offering program.

Key Dates

Recommendation

Keywords

KalVista Pharmaceuticals, EKTERLY, sebetralstat, Hereditary Angioedema, HAE, Oral Therapy, On-demand Treatment, Rare Disease, Biopharmaceutical, FDA Approval, NDA, Phase 3 Clinical Trial, KONFIDENT, Orphan Drug Designation, Fast Track Designation, EMA, MAA, Japan MHLW, Kaken Pharmaceutical, DRI Healthcare, Royalty Financing, Plasma Kallikrein Inhibitor, Factor XIIa Inhibitor, Commercialization, Drug Development, Clinical Trials, Biotech, Pharmaceuticals, Financial Results, 10-K Filing, Corporate Governance, Risk Management, Intellectual Property